Literature DB >> 22233767

Decrease of the immunophilin FKBP52 accumulation in human brains of Alzheimer's disease and FTDP-17.

Julien Giustiniani1, Marlène Sineus, Elodie Sardin, Omar Dounane, Maï Panchal, Véronique Sazdovitch, Charles Duyckaerts, Béatrice Chambraud, Etienne-Emile Baulieu.   

Abstract

Human neurodegenerative diseases characterized by abnormal intraneuronal inclusions of the tau protein, or "tauopathies", include Alzheimer's disease (AD), Pick's disease, progressive supranuclear palsy, corticobasal degeneration as well as fronto-temporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17). Several abnormalities of tau may contribute to the pathological processes, yet the mechanisms involved in tau cellular toxicity remain unclear. Previously, we demonstrated an interaction between various isoforms of tau and the immunophilin FKBP52 (FK506-Binding Protein), suggesting a direct involvement of FKBP52 in tau function. Here we analyze the expression of FKBP52 in human brains of patients with different tauopathies, including AD. Immunohistofluorescence studies carried out on cerebral cortex in different tauopathies reveal that FKBP52 is not sequestered by filamentous tau inclusions while FKBP52 is colocalized with tau in the control case brains. We found that FKBP52 expression level is abnormally low in frontal cortex of AD and FTDP-17 brains, as compared to controls, despite no alteration in the FKBP52 mRNA expression level. The possible involvement of FKBP52 in pathological tau expression/function is discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22233767     DOI: 10.3233/JAD-2011-111895

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  17 in total

Review 1.  Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease.

Authors:  Laura J Blair; Jonathan J Sabbagh; Chad A Dickey
Journal:  Expert Opin Ther Targets       Date:  2014-07-29       Impact factor: 6.902

Review 2.  The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease.

Authors:  Laura J Blair; Jeremy D Baker; Jonathan J Sabbagh; Chad A Dickey
Journal:  J Neurochem       Date:  2015-02-24       Impact factor: 5.372

Review 3.  Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools.

Authors:  Isabelle Landrieu; Elian Dupré; Davy Sinnaeve; Léa El Hajjar; Caroline Smet-Nocca
Journal:  Front Chem       Date:  2022-05-12       Impact factor: 5.545

4.  Immunophilin FKBP52 induces Tau-P301L filamentous assembly in vitro and modulates its activity in a model of tauopathy.

Authors:  Julien Giustiniani; Béatrice Chambraud; Elodie Sardin; Omar Dounane; Kevin Guillemeau; Hiroko Nakatani; Dominik Paquet; Amina Kamah; Isabelle Landrieu; Guy Lippens; Etienne-Emile Baulieu; Marcel Tawk
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-12       Impact factor: 11.205

Review 5.  Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review.

Authors:  Erwin Lemche
Journal:  Curr Genomics       Date:  2018-11       Impact factor: 2.236

6.  Decrease of neuronal FKBP4/FKBP52 modulates perinuclear lysosomal positioning and MAPT/Tau behavior during MAPT/Tau-induced proteotoxic stress.

Authors:  Béatrice Chambraud; Corentin Daguinot; Kevin Guillemeau; Melanie Genet; Omar Dounane; Geri Meduri; Christian Poüs; Etienne Emile Baulieu; Julien Giustiniani
Journal:  Autophagy       Date:  2021-01-25       Impact factor: 16.016

7.  The Influence Mechanism of Abnormal Immunophilin FKBP52 on the Expression Levels of PR-A and PR-B in Endometriosis Based on Endometrial Stromal Cell Model in Vitro.

Authors:  Liling Liu; Junping Cheng; Fu Wei; Lihong Pang; Zhifu Zhi; Wenmei Yang; Weihong Tan
Journal:  Organogenesis       Date:  2021-01-19       Impact factor: 2.500

8.  In silico investigation of traditional Chinese medicine compounds to inhibit human histone deacetylase 2 for patients with Alzheimer's disease.

Authors:  Tzu-Chieh Hung; Wen-Yuan Lee; Kuen-Bao Chen; Yueh-Chiu Chan; Cheng-Chun Lee; Calvin Yu-Chian Chen
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

9.  In Silico Insight into Potent of Anthocyanin Regulation of FKBP52 to Prevent Alzheimer's Disease.

Authors:  Tzu-Chieh Hung; Tung-Ti Chang; Ming-Jen Fan; Cheng-Chun Lee; Calvin Yu-Chian Chen
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-12       Impact factor: 2.629

10.  Ligand-based and structure-based investigation for Alzheimer's disease from traditional chinese medicine.

Authors:  Kai Hsin Liao; Kuen-Bao Chen; Wen-Yuan Lee; Mao-Feng Sun; Cheng-Chun Lee; Calvin Yu-Chian Chen
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.